Probucol: pharmacology and clinical application
- PMID: 2406299
- DOI: 10.1002/j.1552-4604.1990.tb03431.x
Probucol: pharmacology and clinical application
Abstract
Increased levels of cholesterol, LDL-cholesterol, and VLDL-cholesterol are known risk factors for the development of atherosclerotic vascular disease. Probucol is an orally active agent that can reduce total cholesterol and LDL-cholesterol. The drug also reduces HDL-cholesterol. However, it may modify the lipoprotein in such a way that removal of cholesterol from peripheral tissues is still enhanced. Probucol also has antioxidant activity, which may inhibit the oxidative modification of LDL that contributes to lipid deposition in blood vessel walls. Probucol is a well tolerated agent. However, its ability to prolong life in human subjects still needs to be determined.
Similar articles
-
Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesions.Am J Cardiol. 1988 Jul 25;62(3):31B-36B. doi: 10.1016/s0002-9149(88)80048-1. Am J Cardiol. 1988. PMID: 3394651
-
Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis.Ann Intern Med. 1982 Apr;96(4):475-82. doi: 10.7326/0003-4819-96-4-475. Ann Intern Med. 1982. PMID: 7039445 Review.
-
Effect of probucol on serum lipoprotein levels in normal and dyslipoproteinemic mice.Atherosclerosis. 1981 Oct;40(2):101-13. doi: 10.1016/0021-9150(81)90029-0. Atherosclerosis. 1981. PMID: 6946776
-
The hypolipidemic action of probucol. Drug transport and lipoprotein composition in type IIa hyperlipoproteinemia.Atherosclerosis. 1985 Dec;58(1-3):261-8. doi: 10.1016/0021-9150(85)90071-1. Atherosclerosis. 1985. PMID: 4091882
-
Probucol in long-term treatment of hypercholesterolemia.Gen Pharmacol. 1988;19(3):317-20. doi: 10.1016/0306-3623(88)90023-7. Gen Pharmacol. 1988. PMID: 3046993 Review.
Cited by
-
Pharmacological and Advanced Cell Respiration Effects, Enhanced by Toxic Human-Bile Nano-Pharmaceuticals of Probucol Cell-Targeting Formulations.Pharmaceutics. 2020 Jul 29;12(8):708. doi: 10.3390/pharmaceutics12080708. Pharmaceutics. 2020. PMID: 32751051 Free PMC article.
-
Adriamycin-induced heart failure: mechanism and modulation.Mol Cell Biochem. 2000 Apr;207(1-2):77-86. doi: 10.1023/a:1007094214460. Mol Cell Biochem. 2000. PMID: 10888230 Review.
-
An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer.Drug Des Devel Ther. 2014 Sep 29;8:1673-83. doi: 10.2147/DDDT.S68247. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25302020 Free PMC article.
-
Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes.AAPS PharmSciTech. 2015 Feb;16(1):45-52. doi: 10.1208/s12249-014-0205-9. Epub 2014 Aug 29. AAPS PharmSciTech. 2015. PMID: 25168450 Free PMC article.
-
Prospects for the use of antioxidant therapies.Drugs. 1995 Mar;49(3):345-61. doi: 10.2165/00003495-199549030-00003. Drugs. 1995. PMID: 7774511 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources